Compare LITB & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LITB | RNTX |
|---|---|---|
| Founded | 2007 | 2001 |
| Country | Singapore | United States |
| Employees | N/A | 10 |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.1M | 65.7M |
| IPO Year | 2013 | N/A |
| Metric | LITB | RNTX |
|---|---|---|
| Price | $3.23 | $0.74 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 3.8K | ★ 385.3K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.50 | N/A |
| Revenue Next Year | $11.59 | N/A |
| P/E Ratio | $10.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.15 | $0.73 |
| 52 Week High | $4.17 | $2.18 |
| Indicator | LITB | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.15 | 33.10 |
| Support Level | $2.81 | N/A |
| Resistance Level | $3.36 | $1.32 |
| Average True Range (ATR) | 0.22 | 0.08 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 35.00 | 8.95 |
LightInTheBox Holding Co Ltd is a e-commerce company, providing a diverse range of affordable lifestyle products directly to consumers. Its brands include Ador, a women's fashion brand targeting women aged 35-55; the second is a golf apparel brand focusing on female golfers aged 35 and above; the third is a women's light party dress brand for the age group of 30 and above. It offers customers products through websites and mobile applications. The company operates and reviews its performance in two segments: Product sales which consisted of online retailing of consumer products and sales to third-party sellers, and Services which consisted of the provision of logistic services to companies and individual customers.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.